Skip links

Latest

Make well informed decisions, quickly through industry leading process simulation, economic analysis software.

Get in touch
Vaccine Manufacturing – how will supply chain complexity effect a distributed vaccine manufacturing network?

Vaccine Manufacturing – how will supply chain complexity effect a distributed vaccine manufacturing network?

As of October 2021, 6-7 billion doses of COVID-19 vaccines have been provided under emergency measures. The vaccines roll out has peaked at 45 million doses/day and has remained broadly stable (Our Word in Data & WHO), so we can assume that this is the
UK biomanufacturing team to spearhead development of advanced controls to accelerate drug and vaccine manufacturing

UK biomanufacturing team to spearhead development of advanced controls to accelerate drug and vaccine manufacturing

A UK-based consortium consisting of BiologIC Technologies, Biopharm Services, CPI, Pall Corporation, and SCIEX has announced the launch of a project that aims to develop automated manufacturing controls for use in the manufacture of biologics. The project, worth a total of £3.1million, including equipment contributions,
Antibody Drug Conjugates
Antibody Drug Conjugates aren’t “too expensive” – how can the costs of manufacture be monitored and improved?

Antibody Drug Conjugates aren’t “too expensive” – how can the costs of manufacture be monitored and improved?

The historical development of antibody drug conjugates is a well told yarn, where self-immolating reactions are scribbled on ESACT conference paper with PEGS free-issue pens. These multidisciplinary scientists and the molecules they make are writing a new storyline now. Increased activity With six approvals of

Regeneron’s High Profile Success? Demand for COVID-19 prophylactics – what role for Pichia expression technology to assist access

Regeneron’s High Profile Success? Demand for COVID-19 prophylactics – what role for Pichia expression technology to assist access

With Regeneron’s high profile, single-person, single-site, clinical trial proving successful (along with much supporting other clinical data!), will neutralising antibodies surf the second wave? Our COVID-related blogs focus on capacity and cost of making the treatments and understanding opportunities or bottlenecks in large scale provision